ARWR
Price
$13.25
Change
-$0.09 (-0.67%)
Updated
Apr 25 closing price
Capitalization
1.82B
10 days until earnings call
DNLI
Price
$15.85
Change
+$0.17 (+1.08%)
Updated
Apr 28, 10:32 AM (EDT)
Capitalization
2.28B
15 days until earnings call
Ad is loading...

ARWR vs DNLI

Header iconARWR vs DNLI Comparison
Open Charts ARWR vs DNLIBanner chart's image
Arrowhead Pharmaceuticals
Price$13.25
Change-$0.09 (-0.67%)
Volume$862.74K
Capitalization1.82B
Denali Therapeutics
Price$15.85
Change+$0.17 (+1.08%)
Volume$732
Capitalization2.28B
ARWR vs DNLI Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. DNLI commentary
Apr 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and DNLI is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 28, 2025
Stock price -- (ARWR: $13.25 vs. DNLI: $15.68)
Brand notoriety: ARWR: Notable vs. DNLI: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 47% vs. DNLI: 80%
Market capitalization -- ARWR: $1.82B vs. DNLI: $2.28B
ARWR [@Biotechnology] is valued at $1.82B. DNLI’s [@Biotechnology] market capitalization is $2.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $272.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 5 bullish, 3 bearish.
  • DNLI’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than DNLI.

Price Growth

ARWR (@Biotechnology) experienced а +17.88% price change this week, while DNLI (@Biotechnology) price change was +23.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was -4.17%, and the average quarterly price growth was -12.27%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 11, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.28B) has a higher market cap than ARWR($1.82B). DNLI YTD gains are higher at: -23.062 vs. ARWR (-29.521). DNLI has higher annual earnings (EBITDA): -492.89M vs. ARWR (-580.69M). DNLI has more cash in the bank: 832M vs. ARWR (553M). DNLI has less debt than ARWR: DNLI (48.7M) vs ARWR (525M). ARWR has higher revenues than DNLI: ARWR (2.5M) vs DNLI (0).
ARWRDNLIARWR / DNLI
Capitalization1.82B2.28B80%
EBITDA-580.69M-492.89M118%
Gain YTD-29.521-23.062128%
P/E RatioN/AN/A-
Revenue2.5M0-
Total Cash553M832M66%
Total Debt525M48.7M1,078%
FUNDAMENTALS RATINGS
ARWR vs DNLI: Fundamental Ratings
ARWR
DNLI
OUTLOOK RATING
1..100
512
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
9087
P/E GROWTH RATING
1..100
298
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (94) in the Biotechnology industry is in the same range as ARWR (96). This means that DNLI’s stock grew similarly to ARWR’s over the last 12 months.

DNLI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that DNLI’s stock grew similarly to ARWR’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as ARWR (100). This means that DNLI’s stock grew similarly to ARWR’s over the last 12 months.

DNLI's Price Growth Rating (87) in the Biotechnology industry is in the same range as ARWR (90). This means that DNLI’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for DNLI (98). This means that ARWR’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRDNLI
RSI
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 7 days ago
86%
Momentum
ODDS (%)
Bullish Trend 7 days ago
75%
Bullish Trend 7 days ago
80%
MACD
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 7 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 7 days ago
86%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 12 days ago
83%
Bearish Trend 13 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
75%
Bearish Trend 7 days ago
79%
Aroon
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 7 days ago
83%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA284.9525.44
+9.80%
Tesla
GME27.460.38
+1.40%
GameStop Corp
SPY550.643.95
+0.72%
SPDR® S&P 500® ETF
AAPL209.280.91
+0.44%
Apple
BTC.X93754.840000-892.085940
-0.94%
Bitcoin cryptocurrency

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with NTLA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-0.67%
NTLA - ARWR
57%
Loosely correlated
+1.59%
BEAM - ARWR
55%
Loosely correlated
-3.22%
DNLI - ARWR
54%
Loosely correlated
+1.23%
COGT - ARWR
52%
Loosely correlated
+2.88%
CRNX - ARWR
52%
Loosely correlated
-2.99%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.23%
BEAM - DNLI
58%
Loosely correlated
-3.22%
ARWR - DNLI
58%
Loosely correlated
-0.67%
NTLA - DNLI
57%
Loosely correlated
+1.59%
RGNX - DNLI
56%
Loosely correlated
-0.54%
RCKT - DNLI
56%
Loosely correlated
-2.69%
More